Table 1.
Hormone status | |||
---|---|---|---|
Hormone-naïve b | Hormone-refractory c | ||
Clinical characteristics | (n = 13) | (n = 41) | |
Age at diagnosis of primary tumor | 77 (60–85) | 69 (51–86) | |
Age at surgery for SCC | 77 (60–85) | 72 (54–88) | |
PSA at diagnosis of primary tumor (ng/mL) | 140 (21–4,000) | 82 (2–7,300) | |
PSA at surgery for SCC (ng/mL) | 140 (21–3,704) | 190 (0.5–5,139) d | |
Interval between primary tumor diagnosis and surgery for SCC (months) | 0 | 34 (3.5–216) | |
Gleason score of primary tumor: | 6 | 0 | 2 |
7 | 1 | 14 | |
8 | 1 | 6 | |
9 | 1 | 6 | |
10 | 0 | 3 | |
Not available | 10 | 10 | |
Other sites of metastasis at the time of surgery for SCC e | |||
Abdominal organs | 0 | 3 | |
Pelvic organs | 0 | 3 | |
Lymph nodes | 0 | 9 | |
Lung | 0 | 3 | |
Other bones | 11 | 41 | |
Preoperative Frankel grade: f | A | 0 | 0 |
B | 0 | 3 | |
C | 12 | 33 | |
D | 1 | 5 | |
E | 0 | 0 |
a Values are given as median (min–max) or absolute numbers (number of patients).
b Diagnosed with prostate cancer as a result of pain or neurological symptoms from spinal metastasis.
c Patients with disease progression after long-term androgen deprivation therapy.
d PSA values were not available for 3 patients.
eVisceral metastases were registered in 12 patients in the hormone-refractory group.
Patients may have more than one metastasis.
fGrade A: complete lesion (paraplegia); grade B: only sensory function; grade C: motor function present but not of practical use (non-ambulatory); grade D: motor function present, sufficient to allow walking (ambulatory); grade E: no neurological symptoms.